Jade Jones
Overview
Explore the profile of Jade Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng O, Fiser C, Paysour J, Aluwalia R, Hilliard A, Arciero C, et al.
Ann Surg Oncol
. 2024 Aug;
31(11):7570-7581.
PMID: 39138769
Background: The National Accreditation Program for Breast Cancer (NAPBC) standards were recently revised to promote breast cancer (BC) risk assessment and subsequent referral for high-risk services. This project sought to...
2.
Collin L, Jones J, Nash R, Switchenko J, Ward K, McCullough L
Breast Cancer Res Treat
. 2024 Mar;
205(3):609-618.
PMID: 38517602
Purpose: The majority of breast cancer patients are diagnosed with early-stage estrogen receptor (ER) positive disease. Despite effective treatments for these cancers, Black women have higher mortality than White women....
3.
Katz N, Jones J, Mansfield L, Gold M
J Patient Exp
. 2022 Apr;
9:23743735221092572.
PMID: 35450093
When people become patients, they become vulnerable to their healthcare system and healthcare clinicians. In this case study, we describe an example of patient distress caused by language overheard in...
4.
Obeng-Gyasi S, Coles C, Jones J, Sacks R, Lightowlers S, Bliss J, et al.
Am Soc Clin Oncol Educ Book
. 2021 May;
41:1-11.
PMID: 33956493
In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant therapy, such as monitoring for...
5.
Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn I, et al.
Leuk Lymphoma
. 2018 Jul;
60(2):519-522.
PMID: 29978754
No abstract available.
6.
Niemann C, Herman S, Maric I, Gomez-Rodriguez J, Biancotto A, Chang B, et al.
Clin Cancer Res
. 2015 Dec;
22(7):1572-82.
PMID: 26660519
Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase...
7.
Herman S, Mustafa R, Jones J, Wong D, Farooqui M, Wiestner A
Clin Cancer Res
. 2015 Jun;
21(20):4642-51.
PMID: 26089373
Purpose: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells from...
8.
Farooqui M, Valdez J, Martyr S, Aue G, Saba N, Niemann C, et al.
Lancet Oncol
. 2015 Jan;
16(2):169-76.
PMID: 25555420
Background: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy, resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib...
9.
Collins D, Hoskins A, Bowman J, Jones J, Stemberger N, Richmond P, et al.
PLoS One
. 2013 Dec;
8(12):e82280.
PMID: 24349245
Background: Invasive pneumococcal disease (IPD) continues to occur at high rates among Australian Aboriginal people. The seven-valent pneumococcal conjugate vaccine (7vPCV) was given in a 2-4-6-month schedule from 2001, with...
10.
Niemann C, Jones J, Wiestner A
Adv Exp Med Biol
. 2013 Sep;
792:259-91.
PMID: 24014301
The B cell antigen receptor (BCR) and its downstream pathways are pivotal in the pathogenesis of chronic lymphocytic leukemia (CLL). Recently, inhibitors of kinases in the BCR pathway have shown...